Provided by Tiger Fintech (Singapore) Pte. Ltd.

ReShape Lifesciences, Inc.

6.05
-0.0050-0.08%
Volume:15.04K
Turnover:88.25K
Market Cap:4.46M
PE:-0.02
High:6.05
Open:5.99
Low:5.75
Close:6.05
Loading ...

BRIEF-Reshape Lifesciences Inc Files For Mixed Shelf Offering Of Up To $50 Million - SEC Filing

Reuters
·
10 May

ReShape Lifesciences files $50M mixed securities shelf

TIPRANKS
·
10 May

ReShape Lifesciences Inc trading halted, news pending

TIPRANKS
·
09 May

BRIEF-ReShape Lifesciences Announces 1-For-25 Reverse Stock Split

Reuters
·
07 May

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

THOMSON REUTERS
·
07 May

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

GlobeNewswire
·
02 May

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

GlobeNewswire
·
28 Apr

Top Midday Gainers

MT Newswires Live
·
22 Apr

ReShape Lifesciences Gets USPTO's Notice of Allowance for Diabetes Neuromodulation Patent

MT Newswires Live
·
21 Apr

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

THOMSON REUTERS
·
21 Apr

US Stocks Likely To Open Lower Ahead Of March Inflation Release: Expert Highlights 'Fairly Weak Returns' After 5%+ Gains In S&P 500

Benzinga
·
10 Apr

ReShape Lifesciences to Bring Motion Informatics' Neuromuscular Rehabilitation Devices to US

MT Newswires Live
·
10 Apr

ReShape Lifesciences enters agreement with Haifa

TIPRANKS
·
10 Apr

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

GlobeNewswire
·
10 Apr

ReShape Lifesciences FY24 EPS $(13.83); Revenue $8.01M Down From $8.68M YoY

Benzinga
·
08 Apr

ReShape Lifesciences Inc: Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Remain on Track

THOMSON REUTERS
·
08 Apr

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
08 Apr

Press Release: ReShape Lifesciences(R) Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Dow Jones
·
08 Apr

ReShape Lifesciences : Receives Notice of Allowance for U.S. Patent Related to Proprietary Diabetes Neuromodulation Technology

THOMSON REUTERS
·
10 Mar

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

GlobeNewswire
·
10 Mar